2025 Q4 -tulosraportti
44 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenBioPorto – Presentation of Q1 2026 results https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·9 t sittenThe devil is in the detail. If we look at what Bioporto wrote 2 weeks ago, before KDIGO's recommendation, which will be significant for Bioporto, was blown up here on Nordnet social, CB and KW came with a guidance that if they had 60 hospitals by the end of 2026, then the goal was reached. See the link. Now CB and KW have, in silence, changed this to 60+ hospitals. You can read this in the presentation for the next webcast. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
·1 päivä sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·10 t sittenBagerbrød I have found the smoking gun that proves that Malies Ostermann believes it's time to change the old method to the new one, Bioporto's NGAL test. Here it is stated directly, and not wrapped up, so it stands indirectly. It is Marlies Ostermann in the blue t-shirt. It is statements like these that are the reason I maintain that there will be a 1st-degree recommendation in crisis areas. 2nd-degree recommendations in all other areas. The reason there won't be a 1st-degree recommendation in all areas is because, in their own guidelines, they also have to consider poor countries, which do not have the budget to integrate the NGAL test in all areas at once. https://www.linkedin.com/posts/thiago-reis-md-phd-691759a6_special-moment-icu-round-with-professor-activity-7448864960878698496-7Htf/
1 päivä sitten1 päivä sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.- ·1 päivä sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
·5.5.3D missen can you explain to me why you think this one is so interesting I am very curious good luck·3 päivää sittenI can't remember it exactly, but I was involved when they were still at the research level. four years maybe. why that?·3 päivää sittenNgal has been on the market for approx. 15 years and frankly, Bioporto is still in a form of "research level" and start-up in 2026 without a shadow of PROC.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
44 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenBioPorto – Presentation of Q1 2026 results https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·9 t sittenThe devil is in the detail. If we look at what Bioporto wrote 2 weeks ago, before KDIGO's recommendation, which will be significant for Bioporto, was blown up here on Nordnet social, CB and KW came with a guidance that if they had 60 hospitals by the end of 2026, then the goal was reached. See the link. Now CB and KW have, in silence, changed this to 60+ hospitals. You can read this in the presentation for the next webcast. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
- ·1 päivä sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·10 t sittenBagerbrød I have found the smoking gun that proves that Malies Ostermann believes it's time to change the old method to the new one, Bioporto's NGAL test. Here it is stated directly, and not wrapped up, so it stands indirectly. It is Marlies Ostermann in the blue t-shirt. It is statements like these that are the reason I maintain that there will be a 1st-degree recommendation in crisis areas. 2nd-degree recommendations in all other areas. The reason there won't be a 1st-degree recommendation in all areas is because, in their own guidelines, they also have to consider poor countries, which do not have the budget to integrate the NGAL test in all areas at once. https://www.linkedin.com/posts/thiago-reis-md-phd-691759a6_special-moment-icu-round-with-professor-activity-7448864960878698496-7Htf/
- 1 päivä sitten1 päivä sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.
- ·1 päivä sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
- ·5.5.3D missen can you explain to me why you think this one is so interesting I am very curious good luck·3 päivää sittenI can't remember it exactly, but I was involved when they were still at the research level. four years maybe. why that?·3 päivää sittenNgal has been on the market for approx. 15 years and frankly, Bioporto is still in a form of "research level" and start-up in 2026 without a shadow of PROC.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
44 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenBioPorto – Presentation of Q1 2026 results https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·9 t sittenThe devil is in the detail. If we look at what Bioporto wrote 2 weeks ago, before KDIGO's recommendation, which will be significant for Bioporto, was blown up here on Nordnet social, CB and KW came with a guidance that if they had 60 hospitals by the end of 2026, then the goal was reached. See the link. Now CB and KW have, in silence, changed this to 60+ hospitals. You can read this in the presentation for the next webcast. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
- ·1 päivä sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·10 t sittenBagerbrød I have found the smoking gun that proves that Malies Ostermann believes it's time to change the old method to the new one, Bioporto's NGAL test. Here it is stated directly, and not wrapped up, so it stands indirectly. It is Marlies Ostermann in the blue t-shirt. It is statements like these that are the reason I maintain that there will be a 1st-degree recommendation in crisis areas. 2nd-degree recommendations in all other areas. The reason there won't be a 1st-degree recommendation in all areas is because, in their own guidelines, they also have to consider poor countries, which do not have the budget to integrate the NGAL test in all areas at once. https://www.linkedin.com/posts/thiago-reis-md-phd-691759a6_special-moment-icu-round-with-professor-activity-7448864960878698496-7Htf/
- 1 päivä sitten1 päivä sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.
- ·1 päivä sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
- ·5.5.3D missen can you explain to me why you think this one is so interesting I am very curious good luck·3 päivää sittenI can't remember it exactly, but I was involved when they were still at the research level. four years maybe. why that?·3 päivää sittenNgal has been on the market for approx. 15 years and frankly, Bioporto is still in a form of "research level" and start-up in 2026 without a shadow of PROC.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Dataa ei löytynyt